Trial Profile

NN1250-3585: A Trial Investigating the Efficacy and Safety of NN1250 Compared to Insulin Detemir in Subjects With Type 1 Diabetes Mellitus in a Basal/Bolus Treatment Regimen

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin degludec (Primary) ; Insulin aspart; Insulin detemir
Indications Type 1 diabetes mellitus
Focus Registrational; Therapeutic Use
Acronyms BEGIN; BEGIN-BB-T1; NN1250-3585
Sponsors Novo Nordisk

Most Recent Events

04 Jul 2012 New source identified and integrated: United Kingdom Clinical Research Network.
17 Mar 2012 This trial is recruting in England (Parent trial: EudraCT2009-011672-29).
17 Mar 2012 Actual initiation date changed from Feb 2010 to Nov 2009 as reported by European Clinical Trials Database (Parent trial: EudraCT2009-011672-29).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com